In this study, although there was no association between the concomitant use of immunomodulators with ADA and only ADA (P = 0.252), AAA positivity was significantly lower in the immunomodulator combination group than in the immunomodulator non-combination group (1/27 [3.7%] vs. 11/25 [44%], P <0.05, Mann–Whitney U test). This evidence concerns the gene ADA and triple-A syndrome.